Core Points - Vili Medical's stock price decreased by 2.58% to 13.21 yuan as of October 17, 2025, with a total market capitalization of 3.869 billion yuan [1] - The company ranks 95th out of 126 in the medical device sector and 3875th out of 5158 in the A-share market [1] Company Announcements - Shareholder Guangzhou Songwei Enterprise Management Consulting Co., Ltd. holds 39,064,856 shares, accounting for 13.34% of the total share capital [1] - On October 9, 2025, Guangzhou Songwei pledged 14,600,000 shares, representing 37.37% of its holdings and 4.99% of the total share capital, for debt investment [1] - On October 10, 2025, Guangzhou Songwei released a previous pledge of 19,350,000 shares, which accounted for 49.53% of its holdings and 6.61% of the total share capital [1] - The company will repurchase and cancel 996,600 restricted shares due to unmet performance targets, reducing the total share capital from 292,868,018 shares to 291,871,418 shares [2][3] - The repurchase price for the initial grant is set at 5.55 yuan per share, while the reserved grant is at 5.27 yuan per share, funded by the company's own resources [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603309 证券简称：维力医疗 公告编号：2025-059 广州维力医疗器械股份有限公司 股权激励限制性股票回购注销实施公告 重要内容提示： 回购注销原因：根据公司《第一期限制性股票激励计划（草案）》的相关规 定，因公司层面考核指标未达成原因，经公司董事会和股东大会审议通过，公司决 定对77名激励对象持有的已获授但尚未解除限售的合计996,600股限制性股票予以 回购注销。 本次注销股份的有关情况： | 回购股份数量 | 注销股份数量 | 注销日期 | | --- | --- | --- | | 996,600 股 | 996,600 股 | 2025-10-22 | 一、本次限制性股票回购注销已履行的决策程序和信息披露情况 广州维力医疗器械股份有限公司（以下简称"公司"）分别于 2025 年 7 月 30 日召开的第五届董事会第十六次会议、2025 年 8 月 15 日召开的公司 2025 年第一次 临时股东大会审议通过了《关于回购注销公司第一期限制性股票激励计划已 ...

的法律意见书 国浩津法意字（2025）第 356号 致:广州维力医疗器械股份有限公司 国浩律师（天津）事务所（以下简称"本所"）接受广州维力医疗器械股份有 限公司（以下简称"维力医疗"、"上市公司"或"公司"）的委托,作为公司第一期 限制性股票激励计划(以下简称"本激励计划"或"《激励计划(草案)》")的专 项法律顾问,根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》(以下简称"《证券法》")、中国证券监督管理委员会(以 下简称"中国证监会"）、《上市公司股权激励管理办法》〈以下简称"《管理办 法》")等法律、行政法规、部门规章及其他规范性文件(以下简称"法律法规") 和《广州维力医疗器械股份有限公司章程》（以下简称"《公司章程》"）、《广 州维力医疗器械股份有限公司第一期限制性股票激励计划》的有关规定,就公司 本次回购注销部分已授予限制性股票(以下简称"本次回购注销")所涉及的相关 事项,出具本法律意见书。 國浩律師事務所 GRANDALL LAW FIRM 天津市和平区曲阜道 38 号中国人寿金融中心 28 层 邮编：300042 电话：022-85586588 传真：0 ...

Core Viewpoint - The announcement details the pledge and release of shares by a major shareholder of Guangzhou Weili Medical Instruments Co., Ltd., indicating significant movements in shareholding and potential implications for the company's financial stability and investor confidence [2][3][4]. Summary by Sections Share Pledge Details - As of the announcement date, the shareholder Guangzhou Songwei Enterprise Management Consulting Co., Ltd. holds 39,064,856 shares, representing 13.34% of the total share capital, with 14,600,000 shares pledged, accounting for 37.37% of their holdings and 4.99% of the total share capital [2]. - On October 9, 2025, Guangzhou Songwei registered a pledge of part of its shares, with no involvement in major asset restructuring or performance compensation guarantees [2]. Release of Pledged Shares - On October 20, 2022, Guangzhou Songwei pledged 14,000,000 unrestricted circulating shares to China Merchants Securities Co., Ltd., with the pledge period from October 20, 2022, to October 19, 2023 [3]. - On October 19, 2023, the aforementioned shares were extended for pledge, and an additional 5,350,000 unrestricted circulating shares were pledged [3]. - On October 18, 2024, the pledge of 19,350,000 shares was also extended, with details disclosed in previous announcements [4]. - Recently, on October 10, 2025, Guangzhou Songwei completed the early redemption of the pledged shares, with the release procedures finalized through the China Securities Depository and Clearing Corporation [4]. Cumulative Pledged Shares - As of the announcement date, the cumulative pledged shares by Guangzhou Songwei and its concerted parties are detailed, indicating ongoing management of share pledges [4].

证券代码：603309 证券简称：维力医疗 公告编号：2025-058 广州维力医疗器械股份有限公司 关于股东部分股份质押及解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 截至本公告披露日，公司股东广州松维企业管理咨询有限公司合计持有公司股 份 39,064,856 股，占公司总股本的 13.34%，累计质押公司股份 14,600,000 股， 占其所持股份比例的 37.37%，占公司总股本的 4.99%。 广州维力医疗器械股份有限公司（以下简称"公司"、"维力医疗"）于近日接到 公司股东广州松维企业管理咨询有限公司（以下简称"广州松维"）函告，获悉其将 持有的本公司部分股份办理了质押及解除质押的登记手续，具体事项如下： 一、本次股份质押基本情况： 广州松维于 2025 年 10 月 9 日将持有的本公司部分股份办理了质押登记手续， 具体事项如下: | | 是否 | | | | | | | | 占公 | | | --- | --- | --- | --- | --- | --- | --- | ...

Group 1 - The core point of the article is that Weili Medical (SH 603309) announced significant shareholder information and revenue composition for the year 2024 [1] - As of the announcement date, the shareholder Guangzhou Songwei Enterprise Management Consulting Co., Ltd. holds approximately 39.06 million shares, accounting for 13.34% of the total share capital [1] - The company has pledged a total of 14.6 million shares, which represents 37.37% of the shares held by the shareholder and 4.99% of the total share capital [1] Group 2 - For the fiscal year 2024, Weili Medical's revenue composition is primarily from medical devices, which account for 98.04% of total revenue, while other businesses contribute 1.96% [1] - As of the latest report, Weili Medical has a market capitalization of 3.9 billion yuan [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州维力医疗器械股份有限公司（以下简称"公司"、"维力医疗"）全资子公司 海南维力医疗科技开发有限公司（以下简称"海南维力"）于近日收到海南省药品监 督管理局颁发的《中华人民共和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证的具体情况 注册证编号：琼械注准 20252080088 注册人名称：海南维力医疗科技开发有限公司 证券代码：603309 证券简称：维力医疗 公告编号：2025-057 广州维力医疗器械股份有限公司 关于全资子公司产品获得二类医疗器械注册证的公告 批准日期：2025年09月23日 有效期至：2030年09月22日 二、对公司的影响 此次子公司海南维力取得上述医疗器械注册证，有利于丰富子公司产品种类， 有助于提高公司产品的市场竞争力，对公司经营将产生积极影响。 注册人住所：海口国家高新区美安生态科技新城美安三街 39 号 生产地址：海口国家高新区美安生态科技新城美安三街 39 号 产品名称：一次性使用无菌双腔型喉罩气道导管 结构及组成：由气囊、通气管、 ...

Core Viewpoint - Vily Medical (603309) has received a medical device registration certificate for a new product, a disposable sterile double-lumen laryngeal mask airway, from the Hainan Provincial Drug Administration, which is intended for use in anesthesia, sedation, and emergency ventilation support for patients [1] Group 1 - The product is designed for patients requiring short-term artificial airway establishment during anesthesia or sedation [1] - The device is also applicable in emergency and resuscitation scenarios for providing artificial ventilation support [1]

Core Viewpoint - The company, Weili Medical (603309.SH), has received a medical device registration certificate from the Hainan Provincial Drug Administration for its product, a disposable sterile double-lumen laryngeal mask airway catheter [1]. Group 1 - The product is named "disposable sterile double-lumen laryngeal mask airway catheter" [1]. - The registration was granted to the company's wholly-owned subsidiary, Hainan Weili Medical Technology Development Co., Ltd. [1]. - This development indicates the company's ongoing efforts to expand its product offerings in the medical device sector [1].

Core Viewpoint - The company, Weili Medical, has received a medical device registration certificate for its product, a disposable sterile double-lumen laryngeal mask airway catheter, from the Hainan Provincial Drug Administration [1] Group 1 - Weili Medical's wholly-owned subsidiary, Hainan Weili Medical Technology Development Co., Ltd., is responsible for the newly certified product [1]